Nuvectis Pharma
Latest round
- Series A
Last raised
- May 2021
Total raised
- $15M
Investors
- 1
About Nuvectis Pharma
Based in New Jersey, US, and founded in 2020, Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of precision medicines for the treatment of cancer. As of 2022, Ron Bentsur is the CEO of the company. In May 2021, Nuvectis Pharma, Inc. The company is traded on the NASDAQ under the ticker symbol NVCT. The company is developing a pipeline that includes two drug candidates, such as NXP800, which is an oral small molecule HSF-1 pathway inhibitor, and NXP900, which is an oral small molecule SRC/YES1 kinase inhibitor.
Who invested in Nuvectis Pharma
1 investor across 1 round
See all investors in Nuvectis Pharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 23, 2021
Amount
$15M
Investors
Questions about Nuvectis Pharma
Who invested in Nuvectis Pharma?
Nuvectis Pharma has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Nuvectis Pharma raised?
Nuvectis Pharma has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Nuvectis Pharma last raise money?
Nuvectis Pharma's most recent round on record is a Series A, in May 2021.
What does Nuvectis Pharma do?
Based in New Jersey, US, and founded in 2020, Nuvectis Pharma, Inc.
Where is Nuvectis Pharma headquartered?
Nuvectis Pharma is headquartered in Fort Lee, US.
Which VCs invest in companies like Nuvectis Pharma?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Nuvectis Pharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Nuvectis Pharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.